Alcohol Use Disorder and Rehabilitation

Full Review: Nov 2026 ByMashal Khan, MD, NewYork-Presbyterian Hospital | Abdo Semaan, MD, NYP Weill Cornell Medicine | Peer reviewed byMark Zimmerman, MD, South County Psychiatry
Last updated: Nov 2026
v25243017
View Patient Education

Alcohol use disorder (AUD) is a chronic and relapsing pattern of alcohol use that typically includes craving and manifestations of tolerance and/or withdrawal, along with adverse psychosocial consequences.

Alcohol use disorder (AUD) is a diagnosis applied to people who meet particular criteria for a pattern of alcohol use that causes clinically significant impairment or distress. Alcohol misuse is a broader term that encompasses a number of manifestations of problematic alcohol use; this term has supplanted other terms used clinically or colloquially (eg, alcoholism, alcohol abuse, alcohol dependence, alcohol addiction).

In the United States, according to the National Drug Use and Health Survey (NSDUH), AUD was present in 9.7% of people ≥ 12 years in 2024 (1). Prevalence is highest among young adults and decreases with age. Among people aged 18 to 25 years, the estimated 12-month prevalence of alcohol use disorder was 14.4%, whereas for people ≥ 26 years, the 12-month prevalence was only 9.7%.

At-risk drinking (2) is a category of alcohol use defined solely by quantity and frequency of drinking:

  • > 5 drinks/day (or occasion) for men

  • > 4 drinks/day (or occasion) for women

Compared with lesser amounts, these amounts are associated with increased risk of a wide variety of medical and psychosocial complications, including AUD and the lesser degrees of alcohol misuse.

(See also Alcohol Toxicity and Withdrawal.)

General references

  1. 1. National Survey on Drug Use and Health (NSDUH). Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. Publication Number PEP25-07-007, NSDUH Series H-60. Released July 2025.  Accessed May 27, 2027.

  2. 2. Dawson DA, Li TK, Grant BF. A prospective study of risk drinking: at risk for what?. Drug Alcohol Depend. 2008;95(1-2):62-72. doi:10.1016/j.drugalcdep.2007.12.007

Etiology and Risk Factors for Alcohol Use Disorder

The maladaptive pattern of drinking that constitutes AUD may begin with a desire to reach a state of feeling "high." Some people who drink alcohol find that feeling rewarding, so they focus on repeatedly reaching that state. Many people who develop AUD have certain personality traits: emotional dysregulation, affective instability, and impulsivity (1).

Societal factors—attitudes transmitted through the culture or child rearing—affect patterns of drinking and consequent behavior. AUD can occur in anyone, regardless of their age, sex, background, ethnicity, or social situation (2). Thus, clinicians should screen for AUD in all patients.

Genetic factors

As much as 45 to 65% of risk variance for whether a person develops AUD is thought to be due to genetic factors (3). The incidence of AUD is higher in biological children of people with alcohol problems than in adoptive children in a given family (and also higher than in the general population). There is evidence of genetic or biochemical predisposition, including data that suggest some people who develop AUD are less easily intoxicated (ie, they have a higher threshold for central nervous system effects) (4).

Etiology and risk factors references

  1. 1. Tragesser SL, Sher KJ, Trull TJ, Park A. Personality disorder symptoms, drinking motives, and alcohol use and consequences: cross-sectional and prospective mediation. Exp Clin Psychopharmacol. 2007;15(3):282-292. doi:10.1037/1064-1297.15.3.282

  2. 2. Collins SE. Associations Between Socioeconomic Factors and Alcohol Outcomes. Alcohol Res. 2016;38(1):83-94. doi:10.35946/arcr.v38.1.11

  3. 3. Edenberg HJ, Foroud T. Genetics and alcoholism. Nat Rev Gastroenterol Hepatol. 2013;10(8):487-494. doi:10.1038/nrgastro.2013.86

  4. 4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, Text Revision. American Psychiatric Association Publishing; 2022.

Symptoms and Signs of Alcohol Use Disorder

Patients with AUD seldom complain of drinking, so suspicion usually arises from findings noted during care given for other reasons: recurrent injuries or falls, insomnia, anxiety, depression, tachycardia, poorly controlled hypertension, memory lapses, unexplained tremor, or incidental laboratory abnormalities (eg, elevated gamma-glutamyl transpeptidase, macrocytosis). Complications of chronic heavy use may also be the presenting problem (see Chronic Effects ). Any of these should prompt further questioning and screening.

Serious social consequences in patients with AUD usually occur, particularly with moderate or severe AUD. Frequent intoxication is obvious and destructive; it interferes with the ability to socialize and work. Injuries are common. Eventually, failed relationships, divorce (which is 50% higher when one spouse is a heavy drinker), and job loss due to absenteeism may result.

People may be arrested because of alcohol-related behavior or be apprehended for driving while intoxicated, often losing driving privileges for repeated offenses. In the United States, the federal government considers driving with a blood alcohol concentration (BAC) at or above 80 mg/dL (0.08%, [17.4 mmol/L]) a crime, but specific state laws and penalties vary (1).

Symptoms and signs reference

  1. 1. Tung GJ, Vernick JS, Stuart EA, Webster DW, Gielen AC. Federal actions to incentivise state adoption of 0.08 g/dL blood alcohol concentration laws. Inj Prev. 2017;23(5):309-313. doi:10.1136/injuryprev-2016-042087

Screening

While some alcohol-related problems are diagnosed when people seek medical treatment for their drinking or for obvious alcohol-related illnesses (eg, delirium tremens, cirrhosis), many people with AUD remain undiagnosed for a long time. Female patients with AUD are less likely to manifest alcohol-related illnesses, although the gender gap has been closing in recent years (1). Therefore, many governmental and professional organizations recommend universal alcohol screening during routine health care visits.

A scaled approach (see Table ) can help identify patients who require more detailed questioning. Several validated detailed questionnaires are available, including AUDIT and CAGE (2).

Table
Table
Clinical Calculators

Screening references

  1. 1. White AM. Gender Differences in the Epidemiology of Alcohol Use and Related Harms in the United States. Alcohol Res. 2020;40(2):01. Published 2020 Oct 29. doi:10.35946/arcr.v40.2.01

  2. 2. Choe YM, Lee BC, Choi IG, Suh GH, Lee DY, Kim JW. Combination of the CAGE and serum gamma-glutamyl transferase: an effective screening tool for alcohol use disorder and alcohol dependence. Neuropsychiatr Dis Treat. 2019;15:1507-1515. Published 2019 May 31. doi:10.2147/NDT.S203855

Diagnosis of Alcohol Use Disorder

  • Screening and assessment questions and questionnaires

  • Psychiatric assessment

If AUD or other degrees of alcohol misuse are suspected, the patient should be asked follow-up questions to assess the pattern of alcohol use, degree of impact on ability to function, and symptoms of complications. The physical examination should focus on detection of signs of complications of alcohol misuse or of alcohol withdrawal.

The Diagnostic and Statistical Manual of Mental Disorders. 5th edition,Text Revision (DSM-5-TR) considers AUD to be present if patients have clinically significant impairment or distress as manifested by the presence of ≥ 2 of the following over a 12-month period (1):

  • Taking alcohol in larger amounts or for a longer time than intended

  • Persistently desiring or unsuccessfully attempting to decrease alcohol use

  • Spending a great deal of time obtaining, using, or recovering from alcohol

  • Craving alcohol

  • Failing repeatedly to meet obligations at work, home, or school because of alcohol

  • Continuing to use alcohol despite having recurrent social or interpersonal problems because of alcohol

  • Giving up important social, work, or recreational activities because of alcohol

  • Using alcohol in physically hazardous situations

  • Continuing to use alcohol despite having a physical disorder (eg, liver disease) or mental disorder (eg, depression) caused or worsened by alcohol

  • Having tolerance to alcohol

  • Having alcohol withdrawal symptoms or drinking alcohol because of withdrawal

AUD may be further classified as mild, moderate, or severe; and in early or sustained remission.

Diagnosis reference

  1. 1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, Text Revision. American Psychiatric Association Publishing; 2022.

Treatment of and Rehabilitation for Alcohol Use Disorder

  • Brief interventions

  • Psychotherapy

  • Rehabilitation programs

  • Self-help groups

  • Sometimes medications (eg, naltrexone, disulfiram, acamprosate)

All patients should be counseled to decrease their alcohol use to below at-risk levels.

For patients identified as at-risk drinkers, treatment may begin with a brief discussion of the medical and social consequences and a recommendation to reduce or cease drinking, with follow-up regarding compliance (see table ). Brief interventions are recommended, effective, and can be delivered in-person or by telephone or telemedicine (1, 2).

Psychotherapy involves techniques that enhance motivation and teach patients to avoid circumstances that precipitate drinking; cognitive-behavioral therapy, behavioral couples therapy, community reinforcement therapy, and 12-step facilitation have some demonstration of efficacy (1, 3). Other techniques include motivational enhancement therapy, acceptance and commitment therapy, mindfulness, and dialectical behavioral therapy. Social support of abstinence, including the support of family and friends, is important.

Table
Table

For patients with more severe symptoms of and problems from AUD, particularly after less intensive measures have been unsuccessful, a rehabilitation program is often the best approach. A multicenter study of veterans in the United States showed that after hospitalization, discharge to a residential treatment program was more effective than medication for improving abstinence and reducing readmission (4).

Rehabilitation programs combine psychotherapy, including one-on-one and group therapy, with medical supervision. For most patients, outpatient rehabilitation is sufficient; how long patients remain enrolled in programs varies, typically weeks to months, but longer if needed.

Inpatient rehabilitation programs are reserved for patients with more severe alcohol dependence and those with significant and comorbid medical, psychoactive, and substance abuse problems. Treatment duration is usually shorter (typically days to weeks) than that of outpatient programs and may be dictated in part by patients’ insurance.

Maintenance

Maintaining sobriety is difficult, and relapse is common, particularly in the first few months. Patients should be provided with psychoeducation about cravings and high-risk situations precipitating a return to use. They should also be encouraged to see a return to use as a reason to engage with care rather than as evidence of failure. Abstinence is the safest goal and is necessary for patients with alcohol-related organ damage. For others, moderation management is a legitimate goal. 

In addition to the counseling provided in outpatient and inpatient alcohol treatment programs, self-help groups and certain medications may help prevent relapse in some patients.

Alcoholics Anonymous (AA) is the most widely used self-help organization in the United States for people with AUD (2). AA provides patients with nondrinking friends who are always available and a nondrinking environment in which to socialize. Patients also hear others discuss every rationalization they have ever used for their own drinking. The help they give other patients with AUD may provide them with the self-regard and confidence formerly found only in alcohol. Many patients with alcohol use disorder are reluctant to go to AA and find individual counseling or group or family treatment more acceptable. Alternative organizations exist for patients seeking another approach (see More Information).

Medications should be used in combination with counseling rather than as the sole treatment; general medical and psychiatric comorbidities should also be addressed (5). Primary (first-line) pharmacotherapeutic options strongly supported by evidence include naltrexone and acamprosate. Other agents, either recommended as first-line agents with a weaker evidence base or as second-line agents, include disulfiram, topiramate, or gabapentin.

In terms of medication selection, naltrexone and acamprosate are both first-line agents. Choice depends on patient characteristics. Naltrexone is contraindicated in acute hepatitis, liver failure, and opioid dependence, so acamprosate is preferred in these patients, whereas naltrexone is preferred when renal function is impaired. Naltrexone is also available in a long-acting depot formulation, which is useful when adherence is a concern. Topiramate, gabapentin, and clonidine are used when first-line therapy fails or is contraindicated, and disulfiram is reserved for highly motivated patients who can be supervised.

Naltrexone, an opioid antagonist, decreases the relapse rate and number of drinking days in most patients who take it consistently (1, 5). Naltrexone 50 mg orally once/day is typically given, although higher doses (eg, 100 mg once/day) may be given in some patients. Even with counseling, adherence rates with oral naltrexone are modest. A long-acting depot form is also available: 380 mg IM once/month. Naltrexone is contraindicated in patients with acute hepatitis or liver failure and in those who are opioid dependent.

Acamprosate, a synthetic analogue of gamma-aminobutyric acid (GABA) and glutamate modulator, is dosed as 666 mg orally 2 to 3 times a day (5, 6). Acamprosate may decrease the relapse rate and number of drinking days in patients who relapse (1). Dosing should be adjusted in those with impaired renal function.

Disulfiram, the first medication available to prevent relapse in alcohol dependence, interferes with the metabolism of acetaldehyde (an intermediary product in the oxidation of alcohol) so that acetaldehyde accumulates (7). Drinking alcohol within 12 hours of taking disulfiram causes facial flushing in 5 to 15 minutes, then intense vasodilation of the face and neck with suffusion of the conjunctivae, throbbing headache, tachycardia, hyperpnea, and sweating. With high doses of alcohol, nausea and vomiting may follow in 30 to 60 minutes and may lead to hypotension, dizziness, and sometimes fainting and collapse. The reaction can last up to 3 hours. Few patients risk drinking alcohol while taking disulfiram because of the intense discomfort. Medications that contain alcohol (eg, tinctures, elixirs, some over-the-counter (OTC) liquid cough and cold preparations, which contain as much as 40% alcohol) must also be avoided (5).

Disulfiram is contraindicated during pregnancy and in patients with severe myocardial disease or coronary occlusion (8, 9). It may be given on an outpatient basis after 4 or 5 days of abstinence. The initial dosage is 500 mg orally once/day for 1 to 3 weeks, followed by a maintenance dosage of 250 mg once/day. Effects may persist for 3 to 7 days after the last dose. Periodic physician visits are needed to encourage the continuation of disulfiram as part of an abstinence program.

Adherence usually requires that patients have adequate social support and be able to connect the negative consequences with alcohol use while taking disulfiram (1). Disulfiram is most effective when given to highly motivated patients under close supervision.

Topiramate is an antiseizure medication recommended for AUD as a second-line therapy (1, 5). It improves abstinence and reduces heavy drinking, probably by reducing cravings through inhibition of both glutamate receptor activity and dopamine release. Topiramate is contraindicated in pregnancy.

Gabapentin is recommended as an alternative agent in people for whom first-line therapy is not effective or otherwise contraindicated (1, 5). Gabapentin is a gamma-aminobutyric acid (GABA) receptor agonist that appears to have a dose-dependent effect on heavy drinking. Baclofen, another GABA agonist, is also used outside of the United States (2).

Clonidine, the oldest alpha-2-agonist, given orally or transdermally, has proved successful in reducing symptoms of alcohol withdrawal, particularly hypertension and tachycardia, in patients with mild-to-moderate withdrawal (10).

Nalmefene (an opioid antagonist) and semaglutide (a glucagon-like peptide-1 [GLP-1] receptor agonist) are currently being studied for their ability to decrease alcohol craving (11, 12).

Treatment references

  1. 1. U.S. Department of Veterans Affairs. VA/DoD CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF SUBSTANCE USE DISORDERS. Version 5.0–2021. Accessed May 27, 2026.

  2. 2. Haber PS. Identification and Treatment of Alcohol Use Disorder. N Engl J Med. 2025;392(3):258-266. doi:10.1056/NEJMra2306511

  3. 3. Magill M, Ray L, Kiluk B, et al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition. J Consult Clin Psychol. 2019;87(12):1093-1105. doi:10.1037/ccp0000447

  4. 4. Allaudeen N, Akwe J, Arundel C, et al. Medications for alcohol-use disorder and follow-up after hospitalization for alcohol withdrawal: A multicenter study. J Hosp Med. 2024;19(12):1122-1130. doi:10.1002/jhm.13458

  5. 5. Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018;175(1):86-90. doi:10.1176/appi.ajp.2017.1750101

  6. 6. Plosker GL. Acamprosate: A Review of Its Use in Alcohol Dependence. Drugs. 2015;75(11):1255-1268. doi:10.1007/s40265-015-0423-9

  7. 7. Lanz J, Biniaz-Harris N, Kuvaldina M, Jain S, Lewis K, Fallon BA. Disulfiram: Mechanisms, Applications, and Challenges. Antibiotics (Basel). 2023;12(3):524. Published 2023 Mar 6. doi:10.3390/antibiotics12030524

  8. 8. Quintrell E, Russell DJ, Rahmannia S, Wyrwoll CS, Larcombe A, Kelty E. The Safety of Alcohol Pharmacotherapies in Pregnancy: A Scoping Review of Human and Animal Research. CNS Drugs. 2025;39(1):23-37. doi:10.1007/s40263-024-01126-8

  9. 9. Daily Med. Disulfiram tablet. Accessed May 27, 2026.

  10. 10. Johnson M, Cosentino D, Fuehrlein B. A detox dilemma beyond benzodiazepines; clonidine's quandary in alcohol withdrawal management. Am J Addict. 2025;34(1):101-103. doi:10.1111/ajad.13640

  11. 11. Keating GM. Nalmefene: a review of its use in the treatment of alcohol dependence. CNS Drugs. 2013;27(9):761-772. doi:10.1007/s40263-013-0101-y

  12. 12. Lähteenvuo M, Tiihonen J, Tanskanen A, Mittendorfer-Rutz E, Taipale H. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. 2025;82;(1):94-98. doi:10.1001/jamapsychiatry.2024.3599

More Information

Drug Information for the Topic

quizzes_lightbulb_red
Test your KnowledgeTake a Quiz!
IOS ANDROID
IOS ANDROID
iOS ANDROID